Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Double-Blind, Placebo-Controlled Study Examining the Use of Topiramate in the Treatment of Cluster Headache

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00203190
Recruitment Status : Terminated
First Posted : September 20, 2005
Last Update Posted : January 23, 2009
Sponsor:
Collaborator:
Ortho-McNeil Neurologics, Inc.
Information provided by:
Thomas Jefferson University

Brief Summary:
Topiramate is a medication that has been approved by the Food and Drug Administration (FDA) for the treatment of patients with seizures. The trade name for this drug is Topamax®. Topiramate has not been approved by the FDA for the treatment of cluster headache and is experimental for the purposes of this research study. If a subject participates in this study, he/she will increase his/her dose of topiramate rapidly in the first few weeks to try to stop the cluster attacks and then will continue on a maintenance dose of topiramate in order to determine if it can prevent attacks from occurring during that cluster period. We believe that this will lead not only to a faster but a more complete remission of the cluster period.

Condition or disease Intervention/treatment Phase
Cluster Headache Drug: Topiramate Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Enrollment : 60 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: A Single-Center, Randomized, Double-Blind, Placebo Controlled Trial Examining the Safety and Efficacy of Topiramate in the Treatment of Subjects With Episodic or Chronic Cluster Headache.
Study Start Date : September 2004
Study Completion Date : June 2006

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Headache
Drug Information available for: Topiramate




Primary Outcome Measures :
  1. Change in the average daily frequency of moderate or severe attacks between baseline period to the period of day 14 to 56.

Secondary Outcome Measures :
  1. Change in the average daily frequency of any attacks from the baseline period through the entire treatment period.
  2. Change in the average daily duration of any attacks from the baseline period through the entire treatment period.
  3. Change in the average daily attack severity from baseline period through the entire treatment period.
  4. Change in the average daily frequency of any attacks from the baseline period to each week during the treatment period.
  5. Change in the average daily duration of any attacks from the baseline period to each week during the treatment period.
  6. Change in the average daily attack severity from the baseline period to each week during the treatment period.
  7. Time to the first week from the baseline period with a 50% reduction in average daily frequency of moderate or severe attacks.
  8. Change in use of acute and rescue medications from the baseline period through the entire treatment period.


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Subjects between the ages of 18 and 65 with a diagnosis of cluster headache (episodic or chronic) as defined by the International Classification of Headache Disorders (2nd edition)
  • Subjects must have a lifetime prevalence of at least 2 prior cluster cycles.
  • Subjects must experience one or more attacks/ day during baseline period
  • Subjects must have a typical cluster period lasting at least 8 weeks. Subjects must present in active cluster period and the expected remaining duration of the cluster cycle must be at least 8 weeks from Baseline visit.
  • Subjects with other headache types are eligible provided the subject is able to differentiate these headaches from cluster headaches.
  • Subject is using or agrees to use for the duration of participation a medically acceptable form of contraception (as determined by investigator), if female of child-bearing potential
  • Subject has negative urine pregnancy test prior to study entry, if female of child-bearing potential
  • Subject is able to understand and comply with all study requirements
  • Subject provides written informed consent prior to any screening procedures being conducted

Exclusion Criteria:

  • Women who are pregnant or lactating
  • Subjects who, in the investigators opinion, have a history or have evidence of a medical or psychiatric condition that would expose them to an increased risk of a significant adverse event or would interfere with the assessments of efficacy and tolerability during this trial
  • Subjects who require a change in medication or existing regimen of medication for the prophylaxis of cluster in the 4 weeks prior to Baseline visit and for the duration of the trial
  • Subjects who have cluster headaches that typically exceed 4 hours
  • Subjects who have used the following medications/ treatments from four weeks prior to Baseline visit: corticosteroids and nerve blocks.
  • Subjects using any drug which might interact adversely with, or interfere with the action of, the study medication (e.g., carbonic anhydrase inhibitors)
  • Subjects who have failed an adequate trial of topiramate for cluster headaches due to lack of efficacy or adverse events, as determined by the investigator
  • Subjects with a history of nephrolithiasis.
  • Subjects who are allergic to or have shown hypersensitivity topiramate or agents similar to topiramate
  • Subjects who abuse opioids as determined by investigator
  • Subjects with a history of significant drug or alcohol abuse within the past year
  • Subjects who have participated in an investigational drug trial in the 30 days prior to the screening visit

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00203190


Locations
Layout table for location information
United States, Pennsylvania
Jefferson Headache Center
Philadelphia, Pennsylvania, United States, 19107
Sponsors and Collaborators
Thomas Jefferson University
Ortho-McNeil Neurologics, Inc.
Investigators
Layout table for investigator information
Principal Investigator: William B Young, MD Thomas Jefferson University, Jefferson Headache Center
Layout table for additonal information
ClinicalTrials.gov Identifier: NCT00203190    
Other Study ID Numbers: SDS/TOP-CL/01/CAPSS-322
080-19000-H56501
First Posted: September 20, 2005    Key Record Dates
Last Update Posted: January 23, 2009
Last Verified: January 2009
Additional relevant MeSH terms:
Layout table for MeSH terms
Cluster Headache
Headache
Pain
Neurologic Manifestations
Trigeminal Autonomic Cephalalgias
Headache Disorders, Primary
Headache Disorders
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Topiramate
Anticonvulsants
Hypoglycemic Agents
Physiological Effects of Drugs